Drug · DIN 02243181
TEQUIN
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since June 29, 2006; first marketed January 16, 2004.
- Drug Identification Number (DIN)
- 02243181
- Company (DIN owner)
- Bristol-Myers Squibb CanadaSt-Laurent, Quebec, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Gatifloxacin J01MA16
- Class
- Human
- Record last updated
- March 22, 2025
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| GATIFLOXACIN | 200 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- January 9, 2001: NOC 2301New Drug Submission (NDS)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “tequin”. A notice may cover another product or only some lots: read it to see what it covers.
- Association of Tequin (gatifloxacin) with serious hypoglycemia and hyperglycemia - For Health Professionals - Bristol-Myers Squibb CanadaDecember 20, 2005 · Drugs
- Archived - Association of Tequin (gatifloxacin) with serious hypoglycemia and hyperglycemia - For the public - Bristol-Myers Squibb CanadaDecember 20, 2005 · Drugs
Other DINs named TEQUIN
- DIN 02243182 · Cancelled Post Market